FBT News and Press, First Trust Amex Biotech Index Fund From 06/13/19

By Tony DeSpirito Markets tend to focus on one risk at a time, and it’s fragile U.S.-China relations that are front and center now. New blog contributor Tony DeSpirito offers up two potential takeaways for equity investors. Headlines over the U.S.-China trade dispute have been p...

By Marshall Gordon and Nicholas Wu, PhD Healthcare stocks normally react to political rhetoric, but the speed and magnitude of the recent correction in the sector have been surprising. Despite bipartisan clamoring for broad changes to the healthcare system and the Trump administration'...

From the Big Picture to Individual Stock Breakouts Last year I highlighted the Healthcare Biotech Sector Breakout and correctly forecasted "at least 20% gains in sector ETFs and even higher for many key biotech stocks in the near term." I believe the technical analysis that I will det...

Prologue Since we mentioned it for the first time four months ago , the US yield curve has inverted further, raising fresh concerns about the risk of an upcoming recession . There are arguments to be made that "this time is different” in interpreting inversion. However, there is...

With yet another US Senate hearing having been held in late February , prescription drug prices have been continuously receiving a lot of attention. While an eventual solution to brand name pricing may take a number of years, changes to the generic industry may be coming quicker. Over the pas...

( Thank you for the bone crushing pic ) It’s finally here! No, not spring but the return of “Biotech Merger Mania – 2019 Edition!” At least that’s the theme that’s been hyped throughout the financial media over the last few days as speculation began ...

By Andy Acker, CFA & Daniel Lyons, Ph.D., CFA & John Scotti, D.Phil. The biotech industry is experiencing a renaissance, with the U.S. approving a record number of novel therapies in 2018. But not all drugs are created equal, say members of the Janus Henderson Global Life Sciences...

The recently announced deal of Bristol-Myers Squibb ( BMY ) acquiring Celgene ( CELG ) got me thinking about biotech & big pharma stocks. The following chart perfectly sums up why I believe big pharma will continue to be acquirers of large-cap biotech companies and small/mid cap companies....